Industry
Join forces with ITCC to accelerate the development of innovative therapies for paediatric cancer
ITCC is the consortium of hospital sites actively investigating and delivering novel therapies to children and young people with cancer in Europe. We have 62 sites across 17 countries. Over 20 years up to end 2022, we have investigated 75 therapies, completed 55 studies and recruited 3387 patients. Our sites have huge expertise in conventional drugs, immunotherapies, advanced therapies and novel delivery methods.
We have unrivalled knowledge of the landscape of children and young peoples cancer and can advise on appropriate selection of target population and support completion of regulatory procedures. We offer comprehensive medical care for these patients, support complex clinical trials biological assays, pharmacokinetic and quality of life studies and high-quality data management. Our mission is to innovate therapy for children and young people with cancer as fast and safely as possible. To date, we have collaborated with 28 commercial sponsors, with whom we have completed 38 clinical trials, and currently have a further 15 clinical trials ongoing.
ITCC Industry Strategy
Our industry strategy centers on ensuring that paediatric development programmes in the industry align with scientific advancements, patient needs, and regulatory standards. We prioritise assets for paediatric malignancies and work to facilitate both industry and investigator-supported trials across our network, aiming to enhance patient access to innovative therapies. Additionally, we are committed to collecting safety and efficacy data on innovative medicines prescribed outside of clinical trials.
What does ITCC offer?
We offer services including the design of paediatric development plans or scientifically-justified waivers for adult oncology assets to comply with EU and US regulatory requirements, support for the development of specific paediatric anticancer drugs targeting paediatric oncology needs, implementation of early phase clinical trials and ancillary studies in a large network of highly qualified investigating centers, and data collection in compassionate use and named protocols.
The industry is encouraged to engage at any stage of drug development or regulatory interactions, with early involvement being particularly beneficial.
What do we provide?
- Expert advice from over 40 international specialists in biology, immunology, genetics, paediatric oncology, drug development, and regulatory science.
- Access to comprehensive sequencing data from over 6000 paediatric tumors, including whole exome and RNA sequencing, through the ITCC Pediatric Cancer Data Portal.
- Utilization of the preclinical testing platform ITCC P4 featuring a diverse range of molecularly and pharmacologically characterized paediatric tumor models.
- Access to a network of 21 qualified early phase trial centers for conducting first-in-child trials.
- Access to a network of investigation centers across Europe, Canada, and Australia for phase 1/2 and phase 2 trials.
- Access to a network of academic institutions implementing investigator-supported trials and multi-arm platform trials, suitable for filing purposes.
- Access to the international observatory data platform, SACHA, for collecting high-quality safety and efficacy data on innovative medicines used outside clinical trials.
How to contact us
For any queries, please contact Carole Lecinse, ITCC Director of Operations: carole.lecinse@gustaveroussy.fr